why Cellectar Biosciences Inc [CLRB] is a Good Choice for Investors After New Price Target of $5.67

Cellectar Biosciences Inc [NASDAQ: CLRB] traded at a low on Thursday, posting a -5.37 loss after which it closed the day’ session at $0.30.

The results of the trading session contributed to over 12923623 shares changing hands. Over the past one week, the price volatility of Cellectar Biosciences Inc stands at 9.53% while the volatility over the past one month is 8.82%.

The market cap for CLRB stock reached $13.81 million, with 46.08 million shares outstanding and 45.31 million shares in the current float. Compared to the average trading volume of 2.04M shares, CLRB reached a trading volume of 12923623 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about Cellectar Biosciences Inc [CLRB]?

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CLRB shares is $5.67 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CLRB stock is a recommendation set at 1.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Ladenburg Thalmann have made an estimate for Cellectar Biosciences Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on December 05, 2024. While these analysts kept the previous recommendation, Oppenheimer raised their target price to Outperform. The new note on the price target was released on July 01, 2020, representing the official price target for Cellectar Biosciences Inc stock. Previously, the target price had yet another raise to $10, while ROTH Capital analysts kept a Buy rating on CLRB stock.

The Average True Range (ATR) for Cellectar Biosciences Inc is set at 0.03 The Price to Book ratio for the last quarter was 7.84, with the Price to Cash per share for the same quarter was set at 0.74.

How has CLRB stock performed recently?

Cellectar Biosciences Inc [CLRB] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -2.22. With this latest performance, CLRB shares gained by 4.03% in over the last four-week period, additionally sinking by -85.87% over the last 6 months – not to mention a drop of -92.05% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CLRB stock in for the last two-week period is set at 46.32, with the RSI for the last a single of trading hit 48.52, and the three-weeks RSI is set at 39.86 for Cellectar Biosciences Inc [CLRB]. The present Moving Average for the last 50 days of trading for this stock 0.2878, while it was recorded at 0.3124 for the last single week of trading, and 1.6227 for the last 200 days.

Cellectar Biosciences Inc [CLRB]: Deeper insight into the fundamentals

Cellectar Biosciences Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.77 and a Current Ratio set at 1.77.

Earnings analysis for Cellectar Biosciences Inc [CLRB]

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CLRB. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Cellectar Biosciences Inc go to 22.27%.

Insider trade positions for Cellectar Biosciences Inc [CLRB]

There are presently around $11.00%, or 11.18%% of CLRB stock, in the hands of institutional investors.